Global Cortisone Market Size By Type (Oral Drugs, Injectable Drugs), By Application (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 2023 to 2032

The Global Cortisone Market was valued at USD 1.1 billion in 2023 and is projected to reach USD 1.68 billion by 2031, growing at a CAGR of 5.5% during the forecast period from 2023 to 2031. The demand for cortisone is rising due to its widespread application in treating inflammatory conditions, allergic reactions, and autoimmune disorders. Increasing awareness about hormonal therapy, rising healthcare expenditure, and a growing geriatric population are major factors driving market expansion. Additionally, the growth of generic drug manufacturing and improvements in corticosteroid formulations are further enhancing market potential.

Drivers:

1. Rising Incidence of Autoimmune and Inflammatory Diseases:

Autoimmune diseases such as rheumatoid arthritis and lupus, as well as chronic inflammatory conditions, are increasingly prevalent globally. Cortisone plays a critical role in managing these conditions, thereby boosting demand.

2. Growing Use in Dermatology and Allergy Treatments:

Cortisone-based medications are commonly used to treat eczema, psoriasis, and severe allergic reactions. As dermatological conditions rise globally, especially among urban populations, the cortisone market sees steady demand.

3. Expanding Geriatric Population:

Older adults are more susceptible to inflammation-related diseases and hormone imbalances, fueling the need for cortisone treatments in long-term care settings.

Restraints:

1. Side Effects and Long-Term Health Risks:

Cortisone usage can lead to complications such as weight gain, osteoporosis, high blood pressure, and diabetes, which can hinder its prescription and acceptance, particularly for chronic use.

2. Regulatory Hurdles and Generic Competition:

The market faces challenges due to stringent regulatory requirements for approval and the growing availability of low-cost generics, which exert pricing pressure on manufacturers.

Opportunity:

1. Innovation in Drug Delivery Systems:

Novel drug delivery mechanisms such as transdermal patches, inhalable steroids, and injectable depots are gaining traction, improving patient compliance and expanding therapeutic applications for cortisone.

2. Rising Healthcare Access in Emerging Markets:

The expansion of healthcare infrastructure and pharmaceutical access in emerging economies presents untapped opportunities for cortisone manufacturers.

Market by System Type Insights:

Based on system type, the Oral Cortisone segment dominated the market in 2023, driven by ease of administration and widespread use in managing chronic inflammation. However, the Injectable Cortisone segment is anticipated to register the fastest growth due to its rapid action and rising adoption in acute care settings and sports medicine.

Market by End-Use Insights:

In terms of end use, Hospitals and Clinics accounted for the largest revenue share in 2023. Cortisone treatments are frequently administered in clinical settings for acute inflammation, post-surgical recovery, and emergency allergic reactions. The Homecare segment is also expected to grow rapidly, particularly for chronic disease management using oral corticosteroids.

Market by Regional Insights:

Geographically, North America held the largest share in the global cortisone market in 2023, attributed to high healthcare spending, advanced healthcare infrastructure, and strong presence of pharmaceutical giants. Asia-Pacific is projected to experience the highest growth during the forecast period, driven by rising awareness of hormonal therapies, increasing patient population, and expanding health insurance coverage.

Competitive Scenario:

Key players in the Global Cortisone Market include Pfizer Inc., Merck & Co., Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bayer AG, Sun Pharmaceutical Industries Ltd., and Cipla Ltd. These companies are focusing on expanding their product portfolios, investing in R&D, and pursuing strategic collaborations to enhance their competitive positioning.

Scope of Work – Global Cortisone Market

Key Market Developments:

July 2023: Pfizer launched a next-generation injectable cortisone product featuring extended-release technology for improved efficacy in joint inflammation.

April 2024: Teva Pharmaceuticals received FDA approval for a generic cortisone formulation targeting dermatological conditions.

January 2025: GlaxoSmithKline announced a partnership with a biotech startup to develop novel cortisone analogs with reduced side effects for long-term use.

FAQs:

1) What is the current market size of the Global Cortisone Market?

The Global Cortisone Market was valued at USD 1.1 billion in 2023.

2) What is the major growth driver of the Global Cortisone Market?

The primary growth driver is the rising incidence of autoimmune and inflammatory diseases.

3) Which is the largest region during the forecast period in the Global Cortisone Market?

North America is the largest region during the forecast period.

4) Which segment accounted for the largest market share in the Global Cortisone Market?

The Oral Cortisone segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Cortisone Market?

Key players include Pfizer Inc., Merck & Co., Inc., Sanofi S.A., Novartis AG, and GlaxoSmithKline plc.